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Abstract 
 
In this study we evaluated the analgesic and anti- inflammatory activities of the essential oil (EO) of 
the fruits of Dennettia tripetala in rodents. The plant is a tropical African plant and the fruits are commonly 
eaten as spices and consumed as a stimulant, and its various parts are used in the treatment of fever, cough and 
as anti-emetics.The analgesic effects of the oil was assessed in mice using the hot plate, acetic acid-induced 
writhings and formalin test, while carrageenan-induced paw oedema was used to study the antiinflammatory 
effects in rats. The EO at 25-50 mg/kg exhibited significant (p<0.05) antinociceptive effects comparable to a 
potent opioid agonist, morphine (10 mg/kg) and non-steroidal anti-inflammatory drugs such as, aspirin (100 
mg/kg) and indomethacin (80 mg/kg). The antinociceptive effect of the EO was also blocked by naloxone (2 
mg/kg) in all the models used. The EO demonstrated significant (p<0.05) anti-inflammatory effect in the 
carrageenan-induced paw oedema model of inflammation that is also comparable to dexamethasone (1 mg/kg) 
The results showed that the essential oil of D.tripetala possesses significant antinociceptive and 
antiinflammatory effects in the animal models used. The results also suggest that the analgesic effects may be 
mediated both centrally as well as peripherally, while the antiinflammatory activity may be effective in both 
early and late phases of inflammation. The results obtained may therefore be used to rationalize the use of the 
plant in the treatment of pain and fever in traditional medicine. 
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Introduction  
 
The fruits of the plant Dennettia tripetala G.Baker (Annonaceae) are well known in many communities 
of some southern states of Nigeria. The plant is commonly found within cocoa plantation where it is used as 
means of demarcation of farm boundaries. The fruits, leaves, bark and roots of the plant possess strong 
pepperish and pungent taste. These various parts of the plant are popularly used as spices and condiments. The 
plant also possesses characteristic aroma and fragrances. The fruits are mainly chewed raw in different forms 
(fresh green, fresh ripened brown, black dry fruits and dry seeds). The leaves are commonly used in pepper soup 
delicacies, and as condiment in some special local dishes (Ejechi and Akpomedaye, 2005). The leaves are 
commonly used by the local herbalists in combination with other medicinal plants to treat various ailments 
including fever, infantile convulsion, typhoid, cough, worm infestation, vomiting, and stomach upset (Oyemitan, 
2006). There are also reports that the fruits are sometimes used for masking mouth odour (Oyemitan, 2006).  
The fruits of the plants have been reported to be popularly used as stimulants (Aiyeloja and Bello, 2006; 
Ndukwu and Nwadibia, 2006; Oyemitan et al., 2006). Earlier reports showed that the estimated LD50 values of 
the oil following oral (p.o.) and intraperitoneal (i.p.) routes in rats were 1,265 mg/kg (p.o.) and 775 mg/kg (i.p.), 
while the values in mice were 2,150 mg/kg (p.o.) and 470 mg/kg (i.p.) respectively (Oyemitan, 2006). The 
reported mechanism(s) of the behavioural effects (novelty-induced and exploratory behaviours) of the essential 
oils of the plant have been linked to opioidergic and GABA-ergic pathways (Oyemitan, 2006). This present 
study was therefore carried out to further assess the activities of the essential oil of the plant for analgesic and 
antiinflammatory effects in mice and rats respectively as some of the ethnomedical uses are related to pain-
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inflammation disorders. The results of this study may also be used to justify the ethnomedicinal uses of the plant 
to treat fever and cough by the people traditionally. 
Materials and methods 
Plant materials 
 
Fresh fruits were purchased from Owena market, Owena Town, Ondo-East Local Government and 
Central market, Ondo town, Ondo-West Local Government Area of Ondo State. All collections were made 
within the period of April and May 2005. The fruits of D. tripetala G.Baker (Annonaceae) were authenticated 
by Mr. A. Oladele, the Herbarium officer, Department of Pharmacognosy, Faculty of Pharmacy, and Dr. H.C 
Illoh of the Department of Botany, Faculty of Science, Obafemi Awolowo University (OAU) Ile-Ife, Osun 
State. The voucher specimen of the leaves and the fruits (from Owena and Ondo) were prepared and deposited 
at the Herbarium of the Department of Botany, Faculty of Science, O.A.U, Ile-Ife, as voucher No. 15,356.  
 
Essential Oil of D.tripetala:  
 
              Distillation of essential oils was carried out using a distillation and clevenger apparatus. Fresh fruits of 
D. tripetala were air dried at room temperature and commuted into coarse powders using pestle and mortar. 
Four hundred (400 gram) of the powder was hydrodistilled and it yielded 14.68 g amounting to 3.7%w/w of the 
characteristic pungent aromatic odour of the essential oil. The oils obtained were stored in a lightproof bottle 
and kept in a refrigerator until use (Vale et al., 1999; Agbakwuru et al., 1979;Trease and Evans, 1978).  The 
relative density of the essential oil obtained was determined using the 10 ml capacity density bottle (British 
Pharmacopoeia, 1980). The oil was emulsified with 5% Tween 80 shortly before administration. 
 
Animals 
 
Swiss albino rats (both sexes) weighing 150-200 g and white albino mice (both sexes) weighing 18-25 
g were obtained from the Department of Pharmacology, Faculty of Pharmacy, Obafemi Awolowo University, 
Ile-Ife, Nigeria. The animals were kept under standard laboratory conditions and fed with animal feeds 
(Ladokun feeds, Ibadan, Nigeria) and given water ad libitum prior and throughout the period of 
experimentation. All experiments were carried out in accordance with NIH Guide for the care and Use of 
Laboratory animals. 
 
Drugs 
 
The following drugs were also used: Naloxone, Morphine (Sigma, St. Louis, USA), Acetic acid (BDH 
Chemicals Ltd, Poole, England), Aspirin (Dispirin® ) (Reckitt and Colman, UK), diclofenac (Supreme Pharm. 
Nig. Ltd., Lagos, Nigeria), indomethacin (methacin ®) (Hovid Bhd, Perak, Malaysi) and formalin (BDH 
Chemicals Ltd., Poole, England). 
 
  
Materials and Methods 
Analgesic experiment 
Hot plate test:  
 
 Twenty mice were randomly allocated to four groups (n=5). Mice in group 1 were intraperitoneally (i.p.) 
administered with 10 ml/kg of 5% Tween 80; mice in groups 2-4 were intraperitoneally administered with 12.5, 
25.0 and 50.0 mg/kg of essential oil. Each mouse was dropped gently on the hot plate maintained at 55.0 ± 0.5 
OC and the time taken for the mouse to lick the paw was recorded at time 0 second (before treatment) and at 
time 30, 60, 90 and 120 minutes after treatment. The cut off time was set at 15 s to avoid tissue damage. In 
another sets of experiment, 4 groups containing 5 mice each were randomly selected. Group 1 was administered 
with subcutaneous (s.c) injection of naloxone (2 mg/kg) and tested as above, groups 2 and 3 were   pretreated 
with naloxone (2 mg/kg, s.c) 15 minutes prior to administration of 25.0 or 50.0 mg/kg oil, while group 4 was 
pretreated with subcutaneous administration of naloxone (2 mg/kg, s.c.) 15 minutes prior to morphine (10 
mg/kg, i.p.) and the mice were tested as earlier described (Viana et al., 2000; Silva et al., 2003). 
 
Acetic Acid-Induced writhings in mice 
 
Four groups of 5 mice each were randomly selected (n=5). Mice in group 1 were intraperitoneally 
administered with 5% Tween 80 (10 ml/kg), while mice in groups 2-4 were administered with 12.5, 25.0 and 50 
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mg/kg of essential oil respectively. Thirty minutes after treatment, each mouse was administered 10 ml/kg of 
1% acetic acid (i.p.) and allowed 5 mins delay before assessment for up to 20 mins inside the Plexiglas’s cage 
(25 cm x 25 cm x 30 cm). The number of writhings displayed by each mouse was counted and recorded. Aspirin 
(100 mg/kg, i.p.) and morphine (10 mg/kg, i.p.) were administered to another groups of mice (n=5) that were 
used as positive controls. In another experiment, two groups of 5 mice each were pretreated with naloxone (2 
mg/kg, s.c.) 15 minutes prior to administration of the essential oil (25.0 mg/kg, i.p.) or morphine (10 mg/kg, 
i.p.). After 30 minutes 1% acetic acid (10 ml/kg, i.p) was administered and the number of writhes displayed by 
the mice were counted and recorded as earlier described above for 15 mins period (N’gouemo et al., 1996; Le-
Bars et al., 2001; Yin et al., 2003).  
 
Formalin Test  
 
 The method used was that described by Elisabetsky et al. (1995) and Hunskaar and Hole (1997) with 
little modification. Seven groups of mice consisting of 5 mice each were randomly selected. Mice in group 1 
(control) was administered with 5% Tween 80 (10 ml/kg i.p.), while mice in groups 2-4 were treated with the 
essential oil (12.5, 25.0 and 50.0 mg/kg, i.p.). Mice in groups 5-7 were treated with morphine (10 mg/kg i.p.), 
diclofenac (5.64 mg/kg i.p.) and Indomethacin (80 mg/kg, i.p.)  respectively 30 minutes prior to administration 
of 0.02 ml of 2.5% formalin into the sub-planter space of the right hind paw and the duration of paw licking was 
determined 0-5 minutes (1st Phase or neurogenic phase) and 20-25 mins (2nd phase or inflammatory phase) after 
formalin administration. The 1st phase is regarded as the neurogenic mechanism and the 2nd phase is the 
inflammatory mechanism (Elisabetsky et al., 1995; Hunskaar and Hole, 1997; Yin et al., 2003). In another 
experiment, 3 groups of mice consisting of 5 mice each were selected and pretreated with naloxone (2 mg/kg, 
s.c.) 15 minutes prior to administration of the oil (25 and 50 mg/kg i.p.) and morphine (10 mg/kg i.p.) 
respectively. Thirty mins later, they were treated with 2.5% formalin and assessed as earlier described above. 
 
Antiinflammatory experiment 
Carrageenin-induced paw oedema in rats 
 
The antiinflammatory activity was studied using carrageenin-induced paw oedema (acute 
inflammation) method in rats (Winters et al., 1962). Twenty-five rats were randomly divided into five groups 
(n=5). Rats in group 1 (control) were intraperitoneally (i.p.) administered with 5% Tween 80 (10 mg/kg, i.p.), 
while rats in group 2-4 were intraperitoneally administered with the 12.5, 25.0 and 50.0 mg/kg of essential oil 
and rats in group 5 were intraperitoneally administered with dexamethasone (10 mg/kg, i.p.). Thirty minutes 
later, 1% carrageenin (0.1 ml) was injected into the sub-planter surface of right hind paw of each of all the rats 
in all the groups. Measurement of paw size was done by wrapping a piece of cotton thread round the treated paw 
of each rat and measuring the circumference on a meter rule (Olajide et al., 2000; Yin et al., 2003). The 
measurement was carried out at time 0, 1, 2, 3, 4 and 5 h respectively. Inhibitory activity was calculated at 1, 2 
and 3 h after carrageenan treatment (representing the peaks of oedema size), using the formula: 
 
Percentage inhibition = {(Ct-Co) control – (Ct-Co) treated)}    X  100           
                                                                (Ct-Co) control                                    
   
Where Ct is paw size after a specific time interval in hours after carrageenin injection and Co is paw size before 
carrageenin injection.     
                  
Statistical analysis 
 
The results obtained were presented as means ± SEM and analyzed using analysis of variance 
(ANOVA) followed by Dunnet test. The level of significance was set at 95%, p<0.05 for all treatment carried 
out compared to control group using the Primer of Biostatistics by Stanton A.Glantz (version 3.01) copyright 
(C) 1992 by Mc Graw-Hill Inc. 
 
 
Results 
Analgesic effects of oil in mice 
Hot-plate Test:  
 
The essential oil at all the dose levels used induced significant (p< 0.05) analgesia in mice by causing 
an increase in the reaction time to thermal stimulus of the hot plate.  Pretreatment with naloxone (2 mg/kg) 
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reversed the analgesia induced by the oil at these dose levels of 25.0 and 50.0 mg/kg significantly at all the time 
intervals of assessment (Table 1).  
 
Acetic Acid-Induced Writhings in Mice  
 
The essential oil dose-dependently inhibited acetic acid-induced writhes in mice significantly (p<0.05) 
compared to control, but the percentage protection was significantly (p<0.05) less than the standard analgesic 
used, aspirin (Table 2). Naloxone (2 mg/kg) alone did not inhibit acetic acid-induced writhings in mice. 
Pretreatment of mice with naloxone (2 mg/kg) prior to administration of the oil blocked the inhibitory effects of 
the oil on acetic acid-induced writhings in the mice.  
 
Formalin test 
 
The essential oil at 12.5, 25.0 and 50 mg/kg (i.p.) dose dependently inhibited paw-licking time at the two phases 
compared to control.  Indomethacin (80 mg/kg, i.p.) a potent non-steroidal anti-inflammatory drug (NSAID), 
diclofenac (5.46 mg/kg, i.p.) another potent NSAID and morphine (10 mg/kg, i.p.) a potent opioid  also showed 
antinociception. The essential oil at the dose of 50 mg/kg (i.p.) showed 100% inhibition in the 2nd phase as 
obtained with standard drugs used such as morphine (10 mg/kg), diclofenac (5.46 mg/kg) and the oil (50 
mg/kg). Pretreatment with naloxone (2 mg/kg, s.c.) 15 minutes prior to injection of morphine (10 mg/kg) and oil 
(25.0 and 50.0 mg/kg) significantly reduced their antinociceptive effects at the two phases (Table 3) 
 
The results of anti-inflammatory effects of the oil in rats. 
 
The oil at the entire dose levels used inhibited significantly (p<0.05) carrageenan-induced rat paw 
oedema dose-dependently compared to the control. Dexamethasone showed greater inhibition than the oil (12.5-
50 mg/kg) at 1h and 2 h but lower inhibition than the oil (25 or 50 mg/kg) at 3h (Table 4).  
 
 
 
 
Table 1:The antinociceptive activity of the essential oil, morphine and their antagonism by naloxone assessed 
by the hot-plate test. 
 
Reaction Time (Second) Treatment 
(N=5 per group) T.0 min T.30 min T.60 min T.90 min 
Control (10 ml/kg 5% Tween 80) 15.00 ± 0.55 13.80 ± 0.58 13.20 ± 0.55 11.50 ± 0.56 
EO 12.5 mg/kg 14.10 ± 0.77 13.10 ± 0.66 18.20 ± 0.71* 18.70 ± 1.11* 
EO 25.0 mg/kg 13.20 ± 0.71 22.40 ± 0.67* 22.60 ± 0.73* 17.20 ± 0.59* 
EO 50.0 mg/kg 12.50 ± 0.50 17.70 ± 0.76* 19.10 ± 0.81* 18.50 ± 0.76* 
NAL 2 mg/kg + EO 25.0 mg/kg 14.30 ± 0.54 11.40 ± 0.58**     9.30 ± 0.59** 10.40 ± 0.76** 
NAL 2 mg/kg + EO 50.0 mg/kg  13.70 ± 0.75 11.76 ± 0.66**   10.80 ± 0.64**  9.40 ± 0.62** 
MPH 10 mg/kg 12.40 ± 0.53 16.90 ± 0.48* 19.30 ± 0.45* 22.90 ± 0.65* 
MPH 10 mg/kg + NAL 2 mg/kg 12.80 ± 0.55 
 
11.58 ± 0.46# 
 
11.60 ± 0.58# 
 
12.20 ± 0.50# 
 
Each value is mean ± S.E.M, n=5. EO is essential oil of D. tripetala, NAL is naloxone and MPH is morphine. 
The EO (12.5, 25.0 and 50 mg/kg, i.p) and morphine (10 mg/kg, i.p) showed significant antinociceptive effect 
when compared to control group. However, their antinociceptive actions were blocked by pretreatment with 
naloxone (2 mg/kg, s.c.) 30 minutes prior to injection of morphine (10 mg/kg, i.p.) or oil (25 or 50.0 mg/kg, 
i.p.).  * P < 0.05 compared with control; **p<0.05 compared with corresponding dose of EO alone; #p<0.05 
compared with morphine alone. 
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Table 2. The antinociceptive activity of the essential oil and morphine and their antagonism by naloxone 
assessed by Acetic Acid-Induced Writhings in mice 
 
Treatment 
(n = 5 for each group) 
Number of writhes (mean ± SEM) Percentage Analgesia 
Control (5% Tween 80) 10 ml/kg 53.40 ± 1.09 - 
 EO (12.5 mg/kg)  37.60 ± 0.93* 29.6% 
 EO (25.0 mg/kg)  16.60 ± 1.31* 64.4% 
 EO (50.0 mg/kg) 19.00 ± 0.42* 68.9% 
Acetylsalicylic acid (ASA) (100 mg/kg) 13.90 ± 1.43* 74.0% 
NAL (2 mg/kg)      55.00 ± 1.02 -3.0% 
NAL (2 mg/kg) + EO (25.0 mg/kg)   55.80 ± 0.88** 0.7% 
MPH (10 mg/kg)      40.60 ± 0.65* 24.0% 
MPH  (10 mg/kg) + NAL  (2 mg/kg)      51.20 ± 1.27# 4.1% 
Each value is mean ± S.E.M, n =5. EO is essential oil of D. tripetala, NAL is naloxone, and MPH is morphine. 
The essential oil at 12.5, 25.0 and 50 mg/kg, i.p. dose dependently reduced acetic acid-induced writhes in mice 
(29.6, 64.4 and 68.9% respectively) compared to control but aspirin (NSAID) at 100 mg/kg, i.p. showed highest 
analgesic activity (74.0%). Pretreatment with naloxone (opioid antagonist) completely blocked the 
antinociceptive effects of EO at the selected dose of 25 mg/kg and also reversed that of morphine. *P < 0.05 
compared with control, **p<0.05 compared with EO at 25 mg/kg and #p<0.05 compared with morphine alone. 
 
 
Table 3: The antinociceptive activity of the essential oil and morphine and their antagonism by naloxone 
assessed by the formalin test in mice. 
Licking time in seconds Percentage inhibition 
 Treatment  
(N=5 mice for each group) 1
st phase 2nd phase 1st phase 2nd phase 
Control  (10 mg/kg 5% Tween 80)  124.2 ± 1.0 32.6 ± 1.0 - - 
EO (12.5 mg/kg) 104.6 ± 1.5* 25.0 ± 0.9* 15.8 23.3 
EO (25 mg/kg) 92.0 ± 0.9* 10.0 ± 0.8* 26.0 69.3 
EO (50.0 mg/kg) 65.2 ± 1.8* 0* 47.5 100 
Indomethacin 80 mg/kg 90.2 ± 1.2* 18.4 ± 1.3* 27.4 43.6 
MPH (10 mg/kg) 18.2 ± 1.2* 0* 85.3 100 
Diclofenac (5.46 mg/kg)  97.2 ± 1.4* 0* 22.7 100 
NAL (2 mg/kg) + EO (25 mg/kg) 114.6 ±1.4** 17.8 ± 0.9** 7.7 45.4 
NAL (2 mg/kg) + EO (50 mg/kg) 68.8 ± 1.3 0* 43.5 100 
NAL (2 mg/kg)  + MPH (10 mg/kg) 133.2 ±  1.3# 36.0 ± 0.9# - - 
Each value is mean ± S.E.M, n=5. EO is essential oil of D. tripetala, NAL is naloxone, and MPH is morphine. 
The essential oil at 12.5, 25.0 and 50 mg/kg i.p. dose dependently inhibited paw-licking time at the two phases 
compared to control.  Indomethacin 80 mg/kg, i.p. and diclofenac 5.46 mg/kg, i.p. are NSAID agents and 
morphine (a potent opioid agonist) 10 mg/kg, i.p. also showed antinociception. Morphine (10 mg/kg), diclofenac 
(5.46 mg/kg) and the oil (50 mg/kg) showed 100% inhibition in the 2nd phase. Pretreatment with naloxone 2 
mg/kg s.c. 15 minutes prior to injection of morphine (10 mg/kg) and EO (25.0 and 50.0 mg/kg) significantly 
reduced their antinociceptive effects at the two phases except the oil at 50 mg/kg, which was not affected at the 
2nd phase.  * P < 0.05 compared with control; **p<0.05 compared with EO at 25 mg/kg and #p<0.05 compared 
with morphine alone. 
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Table 4: The antiinflammatory effects of the essential oil using the carrageenan-induced paw oedema test in 
rats. 
 
Oedema size (mm) and percentage inhibition of paw oedema over a period of time 
intervals (hrs) 
 
Treatment (n=5) 
 
Oedema size in mm 
(%)   0 h     
Oedema size in 
mm (%) 1h 
Oedema size in mm 
(%)   2 h 
Oedema size in mm 
(%)    3 h 
 
Control  
5%Tween 80 (10 
ml/kg) 
24.8 ± 0.4 37.0  ± 0.6 40.0 ± 0.7 39.6 ± 0.5 
EO 
(12.5 mg/kg) 
23.2 ± 0.4 30.4 ± 0.7 
(40.0%) 
34.2 ± 0.6 
(28.0%) 
 
31.0 ± 0.5 
(47.0%) 
 
EO 
(25 mg/kg) 
24.6 ± 0.4 26.8 ± 0.4 
(84.0%) 
31.6 ± 0.6 
(54.0%) 
 
29.6 ± 0.6 
(66.0%) 
 
EO 
(50 mg/kg) 
 
22.2 ± 0.5 25.4 ± 0.5 
(73.8%) 
26.4 ± 0.5 
(72.0%) 
26.8 ± 0.7 
(69.0%) 
Dexamethasone 
(1 mg/kg) 
24.4 ± 0.5 25.6 ± 0.7 
(90.0%) 
27.5 ± 0.7 
(75.0%) 
 
29.3 ± 0.5 
(60.0%) 
EO is the essential oil of D.tripetala. The oil at the entire dose levels used inhibited significantly (p<0.05) 
carrageenan-induced rat paw oedema dose-dependently compared to the control.  Dexamethasone showed 
greater inhibition than the oil (12.5-50 mg/kg) at 1h and 2 h but lower inhibition than the oil (25 or 50 mg/kg) at 
3h. *p<0.05 compared with control.  
 
 
 
Discussion 
 
The hot plate method is very effective for evaluating drugs possessing analgesic property, which act 
centrally (Vale et al., 1999; Haque et al., 2001; Silva et al., 2003; Al-Naggar et al., 2003). Prolongation of 
reaction time in hot plate test inferred possible central analgesic effects of the oil. The oil increased the reaction 
time significantly at the dose levels used compared to control group. Acetic Acid-induced writhing has been 
used to evaluate drugs possessing peripheral analgesic effects (Koster et al., 1959; Viana et al., 2000). In this 
study, the oil exhibited this analgesic effect in mice by inhibiting the acetic acid induced writhes, which is a 
model of visceral pain, however, not as much as that of the standard drug used-acetylsalicyclic acid (ASA). 
Acetic acid has been reported to cause hyperalgesia by liberating endogenous substances such as prostaglandins, 
leukotrieines, 5-HT, histamine, kinins, H+ and K+, etc. which have been implicated in the mediation of pain 
perception (Forth et al., 1986; Rang et al., 1999).  Therefore, in an attempt to understand the possible 
mechanism of the observed analgesic action of the oil in the hot plate experiment, mice were pre-treated with 
naloxone, a potent opioid antagonist prior to administration of the oil (Almeida et al., 2003). From the results 
obtained, it was observed that naloxone blocked both hot plate and acetic acid induced writhings antinociceptive 
effects. Naloxone reversed the analgesic effects of the oil at the two highest dose levels chosen (Table 2). These 
results suggest that the oil may be exhibiting its analgesic effects in similar manner to opioids or opiates. The 
antagonistic effects of naloxone on the analgesic effects of the oil persist even beyond 90 minutes assessment 
period therefore suggesting that the analgesic effect of the oil as demonstrated is probably mediated through the 
opioid system in the central nervous system (CNS). This is in line with the previous reports that opioid receptors 
are also involved in peripheral as well as central (µ and ĸ-opioids and monoamines) mechanisms of analgesia in 
animals (Millan et al., 1994). Prolongation of reaction time in hot plate test confirmed central analgesic action 
that was blocked by the opioid antagonist, naloxone, a specific antagonist of opioidmimetic receptors (Almeida 
et al., 2003).  
Yin et al (2003) reported that many studies have shown that the earlier phase (1st phase) of formalin-
induced pain reflects the direct effect of formalin on nociceptors whereas the late phase (2nd phase) reflects 
inflammatory pain, which has been linked to prostaglandin synthesis (Hong and Abbot, 1995; Yin, et al., 2003).  
Opioid analgesics have been reported to possess antinociceptive effects in both phases having more effect at the 
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2nd phase (Le Bars et al., 2001). Non-steroidal anti-inflammatory drugs (NSAIDS) such as indomethacin is said 
to be effective only in the 1st phase especially if the formalin is injected at high concentration (Yashpal and 
Coderre, 1998). In this study, the oil dose-dependently inhibited nociception induced in the Formalin Test 
significantly compared to control group in the 1st phase (neurogenic) and 2nd phase (inflammatory). These 
results therefore further suggest that the oil contain constituents that exhibit anti-inflammatory properties. 
Commonly used Non-Steroidal anti-inflammatory Drugs (NSAID) such as aspirin and indomethacin are widely 
used to reduce swelling associated with pain and inflammation through inhibition of prostaglandin synthesis by 
direct effect on cyclo-oxygenase (COX) in the arachidonic acid (AA) metabolism (Amos et al., 2001; Nwafor 
and Okwuasaba, 2003). This result showed that the oil possesses an anti-inflammatory effect dose-dependently 
in the 1st phase including the standard drugs such as indomethacin and diclofenac when compared to control 
mice. Morphine, a potent opioid agonist inhibited paw licking (85%) inhibition, which was completely blocked 
by the opioid antagonist, naloxone. However, pretreatment with naloxone prior to administration of the oil did 
not block the analgesic effects in the 1st phase at a dose of 50 mg/kg, i.p. but blocked this effect with 
administration of the oil at 25 mg/kg, i.p. This result suggests that the oil contain constituents that have potent 
analgesic effects that may be acting in a similar manner to opioids. In the 2nd phase, there was a reduction in 
paw licking compared to control. In this phase, pretreatment with naloxone had no effect on the analgesic effect 
of the oil at this dose level. The results showed that the antagonist only had effect on the low dose but had no 
effect on the high dose of the oil administered. When the oil (50 mg/kg) was assessed, morphine and diclofenac 
completely blocked paw licking compared to control in the 2nd phase whereas indomethacin has lower effects at 
this phase. Naloxone (2 mg/kg), only reversed the analgesic effect of the oil at the dose of 25 mg/kg, while it has 
no effect on morphine and oil (50 mg/kg, i.p.) suggesting that both naloxone and the oils probably compete for 
the same receptor sites-opioidergic receptor and further suggests that opioid receptors are involved in the 
mechanism of action. This result showed that the oil has analgesic effects at both phases of the formalin induced 
paw-licking episodes in mice. This result also suggests that there may be central mediation of the anti-
inflammatory effect of the oil because of its effects in the 2nd phase. There is no doubt that morphine exerts its 
main analgesic effects centrally, hence it appears to be more effective at the two phases (Viana et al., 2000). The 
results further showed that the oil has a comparable effects with the standard drugs used.  
Carrageenan-induced paw oedema as an in vivo model of inflammation has been extensively used to 
evaluate the antiedematous effects of natural products. The EO of D. tripetala at all the dose levels used dose-
dependently displayed significant (p<0.05) anti-inflammatory effects by inhibiting the carrageenan-induced paw 
oedema in the rats compared to control (Table 4). This result is not unusual as essential oils from other sources 
such as from Eucalyptus sp. (Silva et al., 2003), radix of Asarum sieboldii (Kim et al., 2003) and Lavandula 
angustifolia (Hajhshemi et al., 2003) among several reports demonstrated significantly, strong analgesic and 
anti-inflammatory properties. The results obtained in this study indicated that the EO of D tripetala may possess 
more lasting or prolonged anti-inflammatory effects than the standard steroidal drugs as the EO (25-50 mg/kg) 
inhibited the paw oedema at 3 hr more significantly than dexamethasone (1 mg/kg). However, these results are 
preliminary and therefore other inflammation models will be explored to further validate this anti-inflammatory 
property of EO and determine probable mechanism(s) involved. The EO of D.tripetala has been reported to 
contain mainly β-phenylnitroethane (80%), l-linalool (11%), β-Eudesmol and nerolidol (4%) (Agbakwuru et al., 
1995). Therefore, it could be suggested that the antinociceptive and anti-inflammatory effects demonstrated by 
the EO may be due to one or more of these compounds. Further works are however underway to carry out 
activity-directed fractionation of the EO in order to determine the active compound(s) responsible for its effects. 
The various analgesic effects obtained in this work provide lead for detailed and comprehensive knowledge into 
Dennettia tripetala as a potential candidate for development into potent patentable analgesic drug. Combining 
the results from hot plate, acetic acid-induced writhes and formalin tests suggest that the oil contains 
constituent(s) with potent analgesic effects that are likely to be mediated both peripherally and centrally.  
In conclusion, the results of the analgesic and antiinflammatory properties of the essential oil of 
D.tripetala further justify the use of the plant in ethnomedicine for treating fever, cough and vomiting and there 
is need for further investigation with isolated components of the oil for possible development into new class of 
analgesic and antiinflammatory drugs.  
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